Drug intelligence / Profile preview

TXP04

Development stage: Preclinical
Lead developer: Genovyn
Modality: Small Molecules

Overview

TXP04 is a preclinical-stage small molecule transporter inhibitor being developed by Genovyn as part of its Tripsovyn program for the treatment of triple-negative breast cancer (TNBC). The therapeutic candidate is designed to target and inhibit specific transporter proteins, operating independently of traditional hormone or HER2 receptor pathways to address aggressive and hard-to-treat forms of breast cancer.

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on TXP04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TXP04.